Association of blood pressure control level with left ventricular morphology and function and with subclinical cerebrovascular disease

Background--left ventricular (lv) hypertrophy and subclinical cerebrovascular disease are early manifestations of cardiac and brain target organ damage caused by hypertension. this study aimed to investigate whether intensive office systolic blood pressure (sbp) control has beneficial effects on lv morphology and function and subclinical cerebrovascular disease in elderly patients with hypertension. methods and results--we examined 420 patients treated for hypertension without history of heart failure and stroke from the cabl (cardiovascular abnormalities and brain lesions) study. all patients underwent 2-dimensional echocardiographic examination and brain magnetic resonance imaging. subclinical cerebrovascular disease was defined as silent brain infarcts and white matter hyperintensity volume. patients were divided into 3 groups: sbp < 120 mm hg (intensive control); sbp 120 to 139 mm hg (less intensive control); and sbp ≥140 mm hg (uncontrolled). prevalence of lv hypertrophy and diastolic dysfunction were lowest in the intensive control,intermediate in the less intensive control,and highest in the uncontrolled groups (12.8%,31.8%,and 44.7%,respectively [p < 0.001],for lv hypertrophy; 46.8%,61.7%,and 72.6%,respectively [p=0.003],for diastolic dysfunction). patients with less intensive sbp control had greater risk of lv hypertrophy than those with intensive control (adjusted odds ratio,3.26; p=0.013). a similar trend was observed for lv diastolic dysfunction but did not reach statistical significance (adjusted odds ratio,1.65; p=0.144). conversely,intensive sbp control was not significantly associated with reduced risk of silent brain infarcts and white matter hyperintensity volume compared with less intensive control. conclusions--compared with less intensive control,intensive sbp control may have a stronger beneficial effect on cardiac than cerebral subclinical disease. © 2017 the authors and medtronic.